TNBC, TRIPLE NEGATIVE BREAST CANCER
Clinical trials for TNBC, TRIPLE NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new TNBC, TRIPLE NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Dual-Action immunotherapy trial offers hope for aggressive breast cancer
Disease control Recruiting nowThis study is testing whether a new immunotherapy drug called QL1706 works better when combined with different chemotherapy approaches for early-stage triple-negative breast cancer. The trial will enroll 30 patients who will receive either QL1706 with one type of chemotherapy or …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First human trial launches for promising new cancer pill targeting multiple tumors
Disease control Recruiting nowThis is an early-stage study testing a new oral drug called BG-68501 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Three-Pronged attack on aggressive breast cancer tested in new trial
Disease control Recruiting nowThis study is testing a three-drug combination given before surgery for triple-negative breast cancer (TNBC). The goal is to see if adding two newer drugs (sintilimab and bevacizumab) to standard chemotherapy can more effectively shrink or eliminate the tumor. Researchers will me…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Radioactive 'Seeker' drug targets advanced cancers in first human test
Disease control Recruiting nowThis is a very early, first-in-human study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD204. It is for adults with advanced solid tumors (like lung, breast, or skin cancer) that have spread and have stopped responding to standard treatments…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Radioactive cancer fighter enters human testing for tough tumors
Disease control Recruiting nowThis early-stage trial is testing a new radioactive drug called 177LuBetaBart in adults with advanced solid cancers that have stopped responding to standard treatments. The study aims to find a safe dose and see if the drug shows early signs of fighting tumors. Participants will …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug combo aims to wipe out tough breast cancer before surgery
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug called ivonescimab to standard chemotherapy before surgery is safe and more effective for people with early-stage triple-negative breast cancer (TNBC). About 34 participants will receive the drug combination for about …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New combo attack on aggressive breast cancer before surgery
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug called toripalimab to standard chemotherapy before surgery can be more effective for treating triple-negative breast cancer. It will involve about 35 women with early-stage disease to see if this combination can completel…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New cancer drug enters human testing for Tough-to-Treat tumors
Disease control Recruiting nowThis is a first-in-human study to find a safe dose of a new drug called BAL0891. It will test the drug alone and in combination with other cancer therapies in 260 adults with advanced solid tumors or a type of leukemia that has returned or not responded to treatment. The main goa…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
MRI scans could spare breast cancer patients from toxic chemotherapy
Disease control Recruiting nowThis study tests whether MRI scans can identify patients with aggressive triple-negative breast cancer who can safely skip the harshest part of chemotherapy. All participants receive initial treatment with four drugs. Those whose MRI shows no remaining cancer after this phase ski…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Three-Pronged attack on tough breast cancer: radiation, immunotherapy, and chemo tested in major trial
Disease control Recruiting nowThis large, late-stage trial is testing a new combination treatment for early-stage triple-negative breast cancer (TNBC), a type that is harder to treat. It combines a short, intense course of radiation (SBRT) with immunotherapy and standard chemotherapy before surgery. The goal …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: West China Hospital • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for 'Chemo-Resistant' breast cancer: radiation + immunotherapy combo trial
Disease control Recruiting nowThis trial tests a 'rescue' strategy for patients with triple-negative breast cancer whose tumors don't shrink after initial chemotherapy. Participants receive a short, precise radiation treatment followed by immunotherapy combined with two chemotherapy drugs, aiming to shrink tu…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Scientists attack 'Chemo-Resistant' breast cancer with new drug cocktail
Disease control Recruiting nowThis study is testing a new three-drug combination for people with a rare and aggressive type of breast cancer called metaplastic breast cancer (MpBC), which has stopped responding to standard treatments. The goal is to see if adding two new drugs (alpelisib and L-NMMA) to a stan…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New cancer drug trial seeks to control advanced tumors
Disease control Recruiting nowThis study is testing a new drug called TUB-030 in adults with advanced solid cancers that have not responded to other treatments. The main goals are to find the safest dose and see if the drug helps control the cancer. It will focus on specific cancers like head and neck cancer …
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New pill targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis is the first study in people for a new oral medication called AVZO-021. It aims to find a safe dose and see if the drug can help control advanced solid tumors, including certain types of breast and ovarian cancer, when other standard treatments are no longer working. The stu…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Groundbreaking trial matches breast cancer drugs to your tumor
Disease control Recruiting nowThis trial aims to find the best drug combinations for different types of breast cancer before surgery. It tests new drugs alongside standard chemotherapy in 5,000 women with early-stage or locally advanced breast cancer. The study uses tumor analysis and MRI scans to match treat…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New combo attack on tough breast cancers
Disease control Recruiting nowThis study is testing whether adding immunotherapy drugs (pembrolizumab with or without olaparib) to standard radiation therapy is safe and more effective at controlling metastatic breast cancer than radiation alone. It is for adults with specific types of breast cancer (triple-n…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 02, 2026 15:27 UTC
-
New mammogram tech aims to replace MRI for checking chemo success
Diagnosis Recruiting nowThis study is testing if a special type of mammogram that uses a contrast dye can work as well as a breast MRI to see if chemotherapy successfully shrank a breast tumor before surgery. It involves about 30 people with locally advanced breast cancer who are getting chemotherapy be…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: EARLY_PHASE1 • Sponsor: Alison Stopeck • Aim: Diagnosis
Last updated Mar 20, 2026 14:48 UTC
-
Simple blood test may reveal if cancer treatment is working
Knowledge-focused Recruiting nowThis study aims to see if tracking a common inflammation marker (CRP) in the blood can predict how well patients with triple-negative breast cancer respond to immunotherapy. It will observe 225 patients already receiving standard immunotherapy and chemotherapy. The goal is to fin…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: University Hospital Tuebingen • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
Lab tests aim to predict which cancer patients will benefit from immunotherapy
Knowledge-focused Recruiting nowThis study collects tumor tissue samples from cancer patients to research whether laboratory tests can predict which patients will respond to immunotherapy drugs. Researchers will analyze how live tumor samples react to immunotherapy treatments in the lab, then compare those resu…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:11 UTC
-
New Light-Based scanner could help doctors see if breast cancer treatment is working
Knowledge-focused Recruiting nowThis study is testing whether a new optical scanning device called NearWave can monitor how breast cancer responds to chemotherapy before surgery. Researchers will use the device on 15 patients receiving chemotherapy to see if it collects good enough data to predict treatment suc…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:08 UTC
-
Blood test could warn of breast Cancer's return
Knowledge-focused Recruiting nowThis study aims to see if a simple blood test can find tiny bits of leftover cancer DNA after treatment. Researchers will track 900 patients with early-stage breast cancer to see if this 'liquid biopsy' can predict if their cancer will come back. The goal is to gather knowledge t…
Matched conditions: TNBC, TRIPLE NEGATIVE BREAST CANCER
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Mar 20, 2026 14:47 UTC